Selected article for: "antiviral agent and drug combination"

Author: Stachulski, Andrew V.; Taujanskas, Joshua; Pate, Sophie L.; Rajoli, Rajith K. R.; Aljayyoussi, Ghaith; Pennington, Shaun H.; Ward, Stephen A.; Hong, Weiqian David; Biagini, Giancarlo A.; Owen, Andrew; Nixon, Gemma L.; Leung, Suet C.; O’Neill, Paul M.
Title: Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2?
  • Cord-id: na07petj
  • Document date: 2020_12_22
  • ID: na07petj
    Snippet: [Image: see text] The rapidly growing COVID-19 pandemic is the most serious global health crisis since the “Spanish flu” of 1918. There is currently no proven effective drug treatment or prophylaxis for this coronavirus infection. While developing safe and effective vaccines is one of the key focuses, a number of existing antiviral drugs are being evaluated for their potency and efficiency against SARS-CoV-2 in vitro and in the clinic. Here, we review the significant potential of nitazoxanid
    Document: [Image: see text] The rapidly growing COVID-19 pandemic is the most serious global health crisis since the “Spanish flu” of 1918. There is currently no proven effective drug treatment or prophylaxis for this coronavirus infection. While developing safe and effective vaccines is one of the key focuses, a number of existing antiviral drugs are being evaluated for their potency and efficiency against SARS-CoV-2 in vitro and in the clinic. Here, we review the significant potential of nitazoxanide (NTZ) as an antiviral agent that can be repurposed as a treatment for COVID-19. Originally, NTZ was developed as an antiparasitic agent especially against Cryptosporidium spp.; it was later shown to possess potent activity against a broad range of both RNA and DNA viruses, including influenza A, hepatitis B and C, and coronaviruses. Recent in vitro assessment of NTZ has confirmed its promising activity against SARS-CoV-2 with an EC(50) of 2.12 μM. Here we examine its drug properties, antiviral activity against different viruses, clinical trials outcomes, and mechanisms of antiviral action from the literature in order to highlight the therapeutic potential for the treatment of COVID-19. Furthermore, in preliminary PK/PD analyses using clinical data reported in the literature, comparison of simulated TIZ (active metabolite of NTZ) exposures at two doses with the in vitro potency of NTZ against SARS-CoV-2 gives further support for drug repurposing with potential in combination chemotherapy approaches. The review concludes with details of second generation thiazolides under development that could lead to improved antiviral therapies for future indications.

    Search related documents:
    Co phrase search for related documents
    • abdominal pain and activity essential: 1
    • abdominal pain and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • absence presence and acetate ester: 1
    • absence presence and active form: 1, 2
    • absence presence and active metabolite: 1
    • absence presence and activity confirm: 1, 2
    • absence presence and activity correlate: 1
    • absence presence and activity essential: 1
    • absence presence and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acetate ester and acute respiratory syndrome: 1
    • action antiviral mode and acute respiratory syndrome: 1, 2, 3, 4, 5
    • action mode and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • action mode mechanism and acute respiratory syndrome: 1
    • active form and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active metabolite and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • activity abolish and acute respiratory syndrome: 1, 2
    • activity confirm and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • activity correlate and acute respiratory syndrome: 1, 2, 3, 4, 5, 6
    • activity essential and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25